[1] |
WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei.
Mechanism of DCLK1 transcriptional regulation in HCC
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
|
[2] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[3] |
HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan.
Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
|
[4] |
CHEN Minfang, CHEN Lihua, XIE Liyun, XU Fenfen, XIA Aixiao, LIN Zhong.
Preparation and the effect of antitumor of DNA plasmid lipidosome vaccine based VEGFR2 extracellular region by immunization activated in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 24-29.
|
[5] |
BAI Xuemin, ZOU Likao, JIN Zhenmu, JIANG Lijia.
Effects of N-acetylcysteine on regulation of EGFR/MAPK signaling pathway in airway mucus hypersecretion in chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1120-1127.
|
[6] |
WANG Lu, ZHENG Xin, WANG Weicong, ZHAO Hongyun, MA Yuxiang, ZHANG Li, HU Pei, JIANG Ji.
Pharmacokinetics of the metabolites of abivertinib in Chinese patients with advanced NSCLC in a single and multiple dose group
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1147-1152.
|
[7] |
YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen.
Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 927-932.
|
[8] |
GAO Zhongyuan, SUN Geng, LI Min, CHEN Xi, LI Ping, WANG Xuerong.
Naringin inhibits the growth of non-small cell lung carcinoma cells through down-regulating p70S6K
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 762-766.
|
[9] |
WANG Ping, XU Xiao-jing, BU Feng-xiao, ZHOU Yu, YE An, ZHOU Bo-ting.
SNP rs1024750 polymorphism in the EGFR gene significantly influences serum calcium levels in postmenopausal Caucasian women
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 772-779.
|
[10] |
WANG Li-ping, WANG Guo, ZHOU Hong-hao.
Epidermal growth factor receptor polymorphism development on pharmacodynamics of tyrosine kinase inhibitor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 938-944.
|
[11] |
WANG Chang-xiu, MA Run-di, YU Li-jian.
Inhibitory effects of tubeimoside 1, a cyclic bisdesmoside isolated from Bolbostemma paniculatum, on metastases of mouse B16 melanoma and lewis lung carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 764-770.
|
[12] |
YANG Jing-ya, LIU Jian-wen, LIU Cheng-chu, CHEN Bi-wen.
Inhibitory effects of carboxymethyl-chitosan on proliferation and in vitro metastatic ability in human highly metastatic lung carcinoma 95-D Cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 640-643.
|
[13] |
ZHANG Hong-quan, LIU Li.
Effects and mechanisms of danshenyin on accelerate gastric ulcer healing
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 812-818.
|
[14] |
CAO Qi-Zhen, LIN Zhi-Bin.
Potential effect and mechanism of IFNγon tumor angiogenesis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 863-867.
|
[15] |
LI Zhe, YUAN Shou-Jun.
Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 361-364.
|